Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18406232 | ENGINEERED CAS PROTEIN AND USE THEREOF | January 2024 | January 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18518831 | GENE-MODIFYING ENDONUCLEASES | November 2023 | May 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18231697 | METHOD OF MAKING LIPID FORMULATIONS WITH RNA ENCODING IMMUNOGENS | August 2023 | November 2023 | Allow | 3 | 0 | 0 | No | No |
| 18231693 | LIPID FORMULATIONS WITH RNA ENCODING IMMUNOGENS | August 2023 | October 2023 | Allow | 2 | 0 | 0 | No | No |
| 18231692 | IMMUNISATION WITH LIPID FORMULATIONS WITH RNA ENCODING IMMUNOGENS | August 2023 | October 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18333467 | EFFECTOR PROTEINS AND METHODS OF USE | June 2023 | November 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18188312 | TRIFUNCTIONAL T CELL-ANTIGEN COUPLER AND METHODS AND USES THEREOF | March 2023 | September 2024 | Abandon | 18 | 2 | 1 | No | No |
| 17848299 | VACCINE FOR ELICITING IMMUNE RESPONSE COMPRISING LIPID FORMULATIONS AND RNA ENCODING MULTIPLE IMMUNOGENS | June 2022 | February 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 17808519 | VACCINE FOR ELICITING IMMUNE RESPONSE COMPRISING RNA ENCODING AN IMMUNOGEN AND LIPID FORMULATIONS COMPRISING MOLE PERCENTAGE OF LIPIDS | June 2022 | February 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 17848294 | VACCINE FOR ELICITING IMMUNE RESPONSE COMPRISING LIPID NANOPARTICLES AND RNA COMPRISING SEGMENT ENCODING AN IMMUNOGEN | June 2022 | November 2022 | Abandon | 5 | 0 | 1 | No | No |
| 17848337 | METHODS OF ELICITING AN IMMUNE RESPONSE | June 2022 | November 2022 | Abandon | 5 | 0 | 0 | No | No |
| 17836793 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | June 2022 | December 2022 | Allow | 6 | 1 | 0 | No | No |
| 17705037 | HUMANIZED MOUSE MODELS FOR ASSESSING IMMUNE CELL THERAPY | March 2022 | September 2024 | Allow | 29 | 3 | 0 | Yes | No |
| 17693173 | MRNA TARGETING MOLECULE COMPRISING N-ACETYLGALACTOSAMINE BINDING POLYPEPTIDE AND PREPARATION METHOD THEREFOR | March 2022 | May 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17560092 | METHODS OF MAKING LIPID FORMULATIONS WITH VIRAL IMMUNOGENS | December 2021 | December 2022 | Abandon | 11 | 1 | 1 | No | No |
| 17560019 | LIPID FORMULATIONS WITH IMMUNOGENS | December 2021 | January 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17560052 | LIPID FORMULATIONS WITH VIRAL IMMUNOGENS | December 2021 | January 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17560059 | METHODS OF ADMINISTERING LIPID FORMULATIONS WITH IMMUNOGENS | December 2021 | January 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17560138 | METHODS OF ADMINISTERING LIPID FORMULATIONS WITH VIRAL IMMUNOGENS | December 2021 | February 2023 | Allow | 14 | 1 | 1 | No | No |
| 17560116 | METHODS OF MAKING LIPID FORMULATIONS WITH IMMUNOGENS | December 2021 | September 2023 | Abandon | 21 | 2 | 1 | Yes | No |
| 17462925 | TREATMENT OF A CANINE CD20 POSITIVE DISEASE OR CONDITION USING A CANINE CD20-SPECIFIC CHIMERIC ANTIGEN RECEPTOR | August 2021 | May 2025 | Allow | 44 | 1 | 0 | No | No |
| 17383059 | Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Tissue Regeneration | July 2021 | June 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17239510 | Therapeutic Nanoparticles and Related Compositions, Methods and Systems | April 2021 | May 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17233373 | COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION FROM AN ALBUMIN LOCUS | April 2021 | April 2023 | Allow | 24 | 5 | 0 | Yes | No |
| 17153212 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | January 2021 | June 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17123918 | ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS WITH NEW ARCHITECTURES FOR SEQUENCE MANIPULATION | December 2020 | June 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17118378 | CCCTC-Binding Factor Variants | December 2020 | January 2025 | Abandon | 49 | 0 | 1 | No | No |
| 16972920 | MODIFIED Cas9 PROTEIN AND USE THEREOF | December 2020 | December 2024 | Abandon | 48 | 0 | 1 | No | No |
| 17112611 | POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA | December 2020 | May 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17084535 | CELL | October 2020 | February 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17077942 | ANTI-TAU CONSTRUCTS | October 2020 | September 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17064496 | EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | October 2020 | April 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 17032034 | PLASMID CONSTRUCTS FOR HETEROLOGOUS PROTEIN EXPRESSION AND METHODS OF USE | September 2020 | August 2024 | Abandon | 47 | 0 | 1 | No | No |
| 16757981 | CAS12C COMPOSITIONS AND METHODS OF USE | August 2020 | August 2024 | Abandon | 52 | 0 | 1 | No | No |
| 16986413 | NOVEL ADENOVIRUS | August 2020 | July 2024 | Abandon | 47 | 0 | 1 | No | No |
| 16944014 | POLYNUCLEOTIDES ENCODING RELAXIN | July 2020 | April 2024 | Allow | 45 | 1 | 0 | No | No |
| 16923387 | LYM-1 AND LYM-2 TARGETED CAR CELL IMMUNOTHERAPY | July 2020 | November 2024 | Abandon | 53 | 1 | 1 | No | No |
| 16912291 | METHODS OF TREATMENTS USING ANTIGEN-BINDING PROTEINS TARGETING CD56 | June 2020 | February 2024 | Allow | 44 | 1 | 0 | Yes | No |
| 16901335 | TUBULAR NANOSTRUCTURE TARGETED TO CELL MEMBRANE | June 2020 | December 2023 | Abandon | 42 | 0 | 1 | No | No |
| 16900363 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | June 2020 | October 2023 | Abandon | 40 | 5 | 1 | Yes | No |
| 16900368 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | June 2020 | June 2023 | Allow | 36 | 5 | 1 | No | No |
| 16876979 | NATURAL KILLER CELLS AND USES THEREOF | May 2020 | June 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16758602 | PROGRAMMABLE ASSEMBLY OF VIRUS COMPOSITES FOR RECEPTOR-TARGETED GENE DELIVERY | April 2020 | August 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16839947 | METHODS AND COMPOSITIONS FOR INCREASING RNA ACTIVITY IN A CELL | April 2020 | May 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16838545 | MATERIALS AND METHODS FOR TREATMENT OF AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA | April 2020 | November 2024 | Allow | 55 | 1 | 1 | No | No |
| 16809674 | NANO-PLASMONIC MOLECULAR PROBES AND METHODS OF USE | March 2020 | August 2024 | Allow | 53 | 2 | 1 | Yes | No |
| 16715521 | METHOD OF PREPARING AND CRYOPRESERVING CANCER ANTIGEN-SPECIFIC CD8+ T CELLS | December 2019 | September 2024 | Abandon | 57 | 6 | 1 | Yes | No |
| 16709727 | COMPOSITIONS AND METHODS FOR TREATING B-LYMPHOID MALIGNANCIES | December 2019 | July 2024 | Abandon | 56 | 1 | 1 | No | No |
| 16690395 | IDENTIFICATION OF A NOVEL B CELL CYTOKINE | November 2019 | September 2023 | Abandon | 46 | 0 | 1 | No | No |
| 16613592 | CELL THERAPY WITH LENTIVIRAL TRANSDUCED CSF2RA TRANSGENE IN THE TREATMENT OF HEREDITARY PULMONARY ALVEOLAR PROTEINOSIS | November 2019 | April 2024 | Allow | 53 | 2 | 1 | Yes | No |
| 16596228 | METHODS OF FULL GENE REPLACEMENT AND TRANSGENIC NON-HUMAN CELLS COMPRISING FULL HUMAN GENES | October 2019 | August 2024 | Abandon | 58 | 2 | 1 | No | Yes |
| 16562560 | NOVEL CAS9 PROTEINS AND GUIDING FEATURES FOR DNA TARGETING AND GENOME EDITING | September 2019 | May 2023 | Allow | 44 | 0 | 1 | No | No |
| 16562494 | METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY | September 2019 | September 2024 | Allow | 60 | 4 | 0 | No | No |
| 16561847 | GENETICALLY MODIFIED GENES AND CELLS, AND METHODS OF USING SAME FOR SILENCING VIRUS GENE EXPRESSION | September 2019 | July 2023 | Allow | 46 | 2 | 2 | Yes | No |
| 16557820 | Method and Apparatus for High Throughput High Efficiency Transfection of Cells | August 2019 | August 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16543839 | METHODS OF GENERATING OLIGODENDROCYTES AND CELL POPULATIONS COMPRISING SAME | August 2019 | September 2023 | Abandon | 49 | 0 | 1 | No | No |
| 16486632 | Targeted Ligand-Payload Based Drug Delivery for Cell Therapy | August 2019 | February 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16486804 | NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES AND USES THEREOF | August 2019 | June 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16538334 | ANIMAL MODELS OF CORNEAL ECTATIC DISEASES, METHODS OF PRODUCING, AND METHODS OF USE THEREOF | August 2019 | October 2023 | Allow | 50 | 1 | 1 | Yes | No |
| 16483209 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION WITH HETEROBIFUNCTIONAL COMPOUNDS | August 2019 | February 2024 | Allow | 54 | 2 | 1 | Yes | No |
| 16525145 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | July 2019 | August 2023 | Abandon | 48 | 2 | 1 | No | Yes |
| 16510646 | COMPOSITIONS AND METHODS TO MODIFY CELLS FOR THERAPEUTIC OBJECTIVES | July 2019 | March 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 16460848 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | July 2019 | October 2022 | Abandon | 39 | 1 | 1 | No | No |
| 16454537 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | June 2019 | December 2023 | Abandon | 53 | 1 | 1 | Yes | No |
| 16448671 | SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF | June 2019 | July 2023 | Abandon | 49 | 2 | 1 | No | No |
| 16466634 | RNAS FOR WOUND HEALING | June 2019 | August 2022 | Allow | 38 | 1 | 1 | Yes | No |
| 16463646 | COMPLEXES FOR GENE DELETION AND EDITING | May 2019 | July 2022 | Allow | 38 | 1 | 1 | Yes | No |
| 16408923 | SWITCH COSTIMULATORY RECEPTORS | May 2019 | May 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16348829 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | May 2019 | June 2023 | Allow | 50 | 2 | 1 | Yes | Yes |
| 16406895 | INTRATHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS 9 | May 2019 | April 2023 | Allow | 47 | 5 | 1 | Yes | No |
| 16302120 | GENE THERAPY | May 2019 | April 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16388376 | METHOD FOR PRODUCING AN IMMUNOCONJUGATE | April 2019 | December 2023 | Abandon | 56 | 1 | 1 | No | No |
| 16336488 | RECOMBINANT DGKK GENE FOR FRAGILE X SYNDROME GENE THERAPY | March 2019 | October 2022 | Allow | 42 | 2 | 1 | Yes | No |
| 16364763 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF | March 2019 | December 2022 | Abandon | 45 | 2 | 1 | No | No |
| 16365065 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF | March 2019 | December 2022 | Abandon | 45 | 2 | 1 | No | No |
| 16335743 | METHODS OF MODIFYING THE DYSTROPHIN GENE AND RESTORING DYSTROPHIN EXPRESSION AND USES THEREOF | March 2019 | October 2023 | Abandon | 55 | 1 | 1 | No | No |
| 16359626 | Acoustically-Driven Buffer Switching for Microparticles | March 2019 | February 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16358395 | TRANSCRIPTION MODULATION IN ANIMALS USING CRISPR/CAS SYSTEMS | March 2019 | July 2022 | Allow | 40 | 2 | 1 | Yes | No |
| 16288052 | PROCESS FOR DNA INTEGRATION USING RNA-GUIDED ENDONUCLEASES | February 2019 | April 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16270444 | WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME | February 2019 | February 2022 | Allow | 36 | 1 | 1 | Yes | No |
| 16270501 | BIO-REDUCIBLE POLYMERS | February 2019 | March 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16322803 | GENE EDITING OF CAR-T CELLS FOR THE TREATMENT OF T CELL MALIGNANCIES WITH CHIMERIC ANTIGEN RECEPTORS | February 2019 | April 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16099880 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | January 2019 | May 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16312630 | MATERIALS AND METHODS FOR TREATMENT OF FRIEDREICH ATAXIA AND OTHER RELATED DISORDERS | December 2018 | September 2022 | Allow | 45 | 2 | 1 | Yes | No |
| 16311770 | CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION | December 2018 | September 2023 | Allow | 57 | 4 | 1 | Yes | No |
| 16306273 | REPRESSORS OF VIRAL INFECTION | November 2018 | November 2022 | Allow | 47 | 2 | 1 | Yes | No |
| 16186352 | Targeted CRISPR Delivery Platforms | November 2018 | May 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16182189 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | November 2018 | February 2023 | Allow | 51 | 7 | 0 | Yes | No |
| 16182146 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | November 2018 | February 2023 | Allow | 51 | 6 | 0 | Yes | No |
| 16180867 | INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY | November 2018 | October 2023 | Allow | 59 | 7 | 0 | Yes | No |
| 16095884 | Thermal Consistency Systems and Methods for the Application of Thermal Support to a Human or Animal Body or to an Organ for Transplantation | October 2018 | January 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16161101 | TREATMENT OF NEUROPATHY WITH DNA CONSTRUCT EXPRESSING HGF ISOFORMS WITH REDUCED INTERFERENCE FROM GABAPENTINOIDS | October 2018 | August 2023 | Abandon | 58 | 2 | 0 | Yes | No |
| 16156757 | HUMAN EPITHELIAL CELL LINE FOR 3-D MODELIZING OF CANCER AND TREATMENT THEREOF | October 2018 | August 2023 | Abandon | 59 | 4 | 1 | Yes | No |
| 15999476 | CUSTOMIZED CLASS SWITCH OF IMMUNOGLOBULIN GENES IN LYMPHOMA AND HYBRIDOMA BY CRISPR/CAS9 TECHNOLOGY | August 2018 | July 2022 | Allow | 47 | 1 | 1 | Yes | No |
| 16100832 | Cell | August 2018 | June 2023 | Abandon | 58 | 4 | 1 | Yes | No |
| 16062983 | Plasmid Constructs For Heterologous Protein Expression And Methods Of Use | June 2018 | March 2023 | Allow | 57 | 3 | 1 | Yes | No |
| 16061681 | GENE CASSETTE FOR HOMOLOGOUS RECOMBINATION KNOCK-OUT IN YEAST CELLS | June 2018 | November 2022 | Abandon | 53 | 3 | 1 | No | No |
| 16006461 | METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY | June 2018 | July 2024 | Abandon | 60 | 7 | 1 | No | No |
| 15780877 | METHOD OF AMPLIFYING A POPULATION OF ANTIGEN-SPECIFIC MEMORY CD4+ T CELLS USING ARTIFICIAL PRESENTING CELLS EXPRESSING HLA CLASS II MOLECULES | June 2018 | May 2023 | Abandon | 59 | 3 | 1 | No | No |
| 15992833 | Chimeric Antigen Receptor Cell Preparation and Uses Thereof | May 2018 | September 2022 | Allow | 51 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEONARD, ARTHUR S.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 31.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEONARD, ARTHUR S works in Art Unit 1631 and has examined 127 patent applications in our dataset. With an allowance rate of 59.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner LEONARD, ARTHUR S's allowance rate of 59.8% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEONARD, ARTHUR S receive 2.51 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by LEONARD, ARTHUR S is 49 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +60.7% benefit to allowance rate for applications examined by LEONARD, ARTHUR S. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 15.8% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 40.9% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 59% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.